MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.42 and traded as high as $1.99. MediciNova shares last traded at $1.91, with a volume of 11,634 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on MediciNova in a research note on Saturday. They set a “hold” rating on the stock.
Read Our Latest Research Report on MNOV
MediciNova Trading Up 1.1 %
MediciNova (NASDAQ:MNOV – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Equities analysts forecast that MediciNova, Inc. will post -0.23 earnings per share for the current fiscal year.
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Read More
- Five stocks we like better than MediciNova
- What Are Dividend Achievers? An Introduction
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How Investors Can Find the Best Cheap Dividend Stocks
- CarMax’s Impressive Rally: What Investors Should Watch Next
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.